Mogrify
Develops cell-reprogramming platforms and in vivo therapies for patients with unmet medical needs
Highlights
- New on EvolcAdded 2026-11-15
About Mogrify
Mogrify develops therapies that use direct cellular reprogramming to restore cell types lost through disease or injury. Its MOGRIFY and epiMOGRIFY platforms use transcriptomic and epigenetic data to identify factors involved in cell conversion and maintenance of cell identity.
The company is developing therapies for otology, ophthalmology, diabetes and other disease areas, and commercializes its platforms through therapy development, co-development partnerships and licensing. It is based in Cambridge, UK, and was incorporated in 2016.
Product: Cell-reprogramming platforms and in vivo reprogramming therapies, commercialized through therapy development, partnerships and licensing.
Jobs at Mogrify
Leadership
- Jose Polo · FounderSource: company website
- Julian Gough · Founder & SAB ChairSource: company website
- Owen Rackham · FounderSource: company website
- Darrin M. Disley · CEOSource: company website
More biotech & pharma companies
Moolec Science
Produces animal proteins and plant-based ingredients in crops such as soybean and safflower for food companies worldwideNew on EvolcMoredun Scientific
Contract research and biosafety testing for animal health, aquaculture and biotechnology companiesMultiplai Health
RNA sequencing and AI blood screening for cardiovascular and other complex diseasesNew on EvolcMursla
Tissue-specific extracellular vesicle tests and analytics for cancer surveillance and precision medicineNew on EvolcMyricx Pharma
Develops antibody-drug conjugate cancer therapies using payloads based on N-myristoyltransferase inhibitorsN2SA
Pharmaceutical licensing and distribution for healthcare providers, distributors and public-sector partners across Southern AfricaNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
CRM & customer data
- HubSpotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- CookieFirstHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.